<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.92020</article-id><article-id pub-id-type="publisher-id">ACM-28836</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190200000_70835967.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  左室射血分数保留的心力衰竭的研究进展
  Progress in the Study of Heart Failure with Left Ventricular Ejection Fraction Retention
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>淑梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韩</surname><given-names>肖肖</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谷</surname><given-names>秀娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>西安市妇幼保健院，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>02</issue><fpage>121</fpage><lpage>126</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    左室射血分数保留的心力衰竭(HFpEF)是左室射血分数正常或接近正常(LVEF ≥ 50%)的心力衰竭。HFpEF与射血分数降低的心力衰竭(HFrEF)相比有相似的发病率和病死率。该文主要介绍HFpEF的病理生理机制和生物标志物在诊断及预后评估中的进展。
    Heart failure with preserved left ventricular ejection fraction (HFpEF) is a heart failure with normal or near normal left ventricular ejection fraction (LVEF &lt; 50%). HFpEF has similar morbidity and mortality as heart failure (HFrEF) with reduced ejection fraction. This article mainly introduces the pathophysiological mechanism of HFpEF and the progress of biomarkers in diagnosis and prognosis evaluation. 
  
 
</p></abstract><kwd-group><kwd>射血分数保留，心力衰竭，病理生理，生物标志物, Ejection Fraction Retention</kwd><kwd> Heart Failure</kwd><kwd> Pathophysiology</kwd><kwd> Biomarkers</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>左室射血分数保留的心力衰竭的研究进展<sup> </sup></title><p>邵淑梅<sup>1</sup>，韩肖肖<sup>2</sup>，谷秀娟<sup>1*</sup></p><p><sup>1</sup>延安大学附属医院，陕西 延安</p><p><sup>2</sup>西安市妇幼保健院，陕西 西安</p><p><img src="//html.hanspub.org/file/4-1570805x1_hanspub.png" /></p><p>收稿日期：2019年1月29日；录用日期：2019年2月6日；发布日期：2019年2月13日</p><disp-formula id="hanspub.28836-formula57"><graphic xlink:href="//html.hanspub.org/file/4-1570805x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>左室射血分数保留的心力衰竭(HFpEF)是左室射血分数正常或接近正常(LVEF ≥ 50%)的心力衰竭。HFpEF与射血分数降低的心力衰竭(HFrEF)相比有相似的发病率和病死率。该文主要介绍HFpEF的病理生理机制和生物标志物在诊断及预后评估中的进展。</p><p>关键词 :射血分数保留，心力衰竭，病理生理，生物标志物</p><disp-formula id="hanspub.28836-formula58"><graphic xlink:href="//html.hanspub.org/file/4-1570805x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570805x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570805x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>2016年ESC指南根据射血分数(LVEF)将心力衰竭分为三类：1) 射血分数降低的心力衰竭(HFrEF)，LVEF &lt; 40%；2) 射血分数中间范围的心力衰竭(HFmrEF)，LVEF 40%~49%；3) HFpEF，LVEF ≥ 50% [<xref ref-type="bibr" rid="hanspub.28836-ref1">1</xref>] 。该病好发于老年、肥胖、女性，常伴有一些基础疾病，如高血压、糖尿病、肾功能不全、贫血及心房颤动。HFpEF病理生理变化复杂、多样。国外研究显示，由于对这类疾病的认识不足，使HFpEF和HFrEF的患病率几乎相同，所以早期诊断HFpEF尤为重要。生物标志物在心衰的诊断、预后等方面起到重要作用，故本文将对此进行综述。</p></sec><sec id="s4"><title>2. 病理生理变化</title><p>由于HFpEF的病因较多，故病理生理变化较复杂，涉及神经内分泌、循环等多方面，各变化之间相互影响。下面是HFpEF比收缩性心力衰竭(SHF)更具代表性的一些病理生理变化。</p><sec id="s4_1"><title>2.1. 心肌重构</title><p>研究证明，大多数HFpEF患者为左心室向心性重构 [<xref ref-type="bibr" rid="hanspub.28836-ref2">2</xref>] ，在心腔容积不过度增大时即可发生心功能受损。故有些学者认为心肌重构是HFpEF发病的重要一环。HFpEF的射血分数正常仅表示心脏的泵血功能尚可维持，心肌的收缩功能可能已经受损 [<xref ref-type="bibr" rid="hanspub.28836-ref3">3</xref>] 。表面上看，HFpEF的代偿改变处于HF的早期阶段，但其影响因素复杂多变。</p></sec><sec id="s4_2"><title>2.2. 心房功能</title><p>当血压、心室内压升高，心脏可发生相应的代偿性改变，包括心房肥大、扩大，伴心肌顺应性降低、肺动脉压升高。HFpEF与心房结构功能的变化关系密切，相互影响。</p></sec><sec id="s4_3"><title>2.3. 心率变化</title><p>研究表明，HFpEF患者的基础心率与住院次数呈正相关 [<xref ref-type="bibr" rid="hanspub.28836-ref4">4</xref>] ，但对HFpEF患者总体预后的观点尚不一致。一些观点认为，HFpEF患者的基础率与总体预后无明显相关系 [<xref ref-type="bibr" rid="hanspub.28836-ref5">5</xref>] 。</p></sec><sec id="s4_4"><title>2.4. 外周血管内皮细胞功能</title><p>目前关于血管内皮细胞功能对循环系统负荷及心脏舒张功能的研究仍不足，基于反应性充血外周动脉张力的量化指标(RHI)通过计算血管收缩、舒张、顺应性等指标变化，可间接反映血管内皮功能，研究表明，HFpEF患者心脏舒张功能和血管事件与RHI存在线性关系 [<xref ref-type="bibr" rid="hanspub.28836-ref6">6</xref>] ，故有理由认为血管内皮细胞功能可影响HFpEF患者的预后。</p></sec></sec><sec id="s5"><title>3. 诊断</title><p>2016年欧洲心力衰竭指南提出了明确的诊断标准，如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Types and diagnostic criteria of heart failur</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >心力衰竭类型</th><th align="center" valign="middle" >HFrEF</th><th align="center" valign="middle" >HFmrEF</th><th align="center" valign="middle" >HFpEF</th></tr></thead><tr><td align="center" valign="middle" >标准</td><td align="center" valign="middle" >1) 症状 &#177; 体征 2) LVEF 3) &lt;40%</td><td align="center" valign="middle" >症状 &#177; 体征 LVEF 40%~49% 1) 利钠肽水平升高 2) 符合以下至少1条 标准： a) 相关的结构性心脏病(LVH或LAE) b) 舒张功能不全</td><td align="center" valign="middle" >症状 &#177; 体征 LVEF≥50% 1) 利钠肽水平升高 2) 符合以下至少1条 标准： a) 相关的结构性心脏病(LVH或LAE) b) 舒张功能不全</td></tr></tbody></table></table-wrap><p>表1. 心力衰竭类型及诊断标准</p><p>注：LVH：左室肥厚；LAE：左房扩大。</p></sec><sec id="s6"><title>4. 生物标志物</title><sec id="s6_1"><title>4.1. 神经激素类生物标志物</title><sec id="s6_1_1"><title>4.1.1. 心房利钠肽(ANP)及中区心房利钠肽原(MR-proANP)</title><p>ANP主要由心房分泌，心室肌也有少量表达，心房压力增高时释放，其生理作用为扩张血管和利尿排钠。血浆ANP极短的半衰期使其临床应用受到限制。NT-proANP是ANP生产过程中的副产物，在体内有较好的稳定性。BACH (Biomarkers in Acute Congestive Heart failure)试验 [<xref ref-type="bibr" rid="hanspub.28836-ref7">7</xref>] 证实MR-proANP与BNP、NT-proBNP在诊断急性心衰(AHF)中有着相等的价值，在BNP及NT-proBNP难以判定的亚组，MR-proANP诊断价值更高。von Haehling等 [<xref ref-type="bibr" rid="hanspub.28836-ref8">8</xref>] 评估了MR-proANP在慢性心力衰竭(CHF)病人中的预测价值，研究表明：MR-proANP预测价值至少与NT-proBNP一样有效。</p></sec><sec id="s6_1_2"><title>4.1.2. BNP及N末端脑钠肽前体(NT-proBNP)</title><p>BNP首先由日本学者Sudoh等于1988年从猪脑中分离，主要由心室肌细胞分泌。BNP的释放主要是由心室容量、心室压力和心脏负荷的增加引起的。BNP与传统的心肌损伤标志物cTnI、cTnT、CK-MB相比，其对不同心功能分级的HF患者更具有敏感性。BNP和NT-BNP是由proBNP裂解产生的，NT-proBNP较BNP半衰期长、稳定性好及易检测，在心衰应用中有更大的价值 [<xref ref-type="bibr" rid="hanspub.28836-ref9">9</xref>] 。2016年ESC指南 [<xref ref-type="bibr" rid="hanspub.28836-ref10">10</xref>] 中诊断HFpEF要求：BNP &gt; 25 pg/mL和(或)NT-proBNP &gt; 125 pg/mL，低于则诊断为HFrEF。BNP不是独立诊断HFpEF的依据，必须结合其它检查结果。</p></sec><sec id="s6_1_3"><title>4.1.3. 和肽素(copeptin, CP)</title><p>CP，1972年由Holwerda首次在猪脑垂体中发现 [<xref ref-type="bibr" rid="hanspub.28836-ref11">11</xref>] 。CP和精氨酸加压素(AVP)一起由下丘脑分泌，二者共同作为精氨酸加压素原的一部分。AVP具有抗利尿和促周围血管收缩作用。其释放受心房牵张感受器调控，心力衰竭时心房牵张感受器敏感性下降，不能抑制AVP释放而使血浆AVP水平升高。AVP具有半衰期短及不稳定的局限性，临床上无法做常规检测 [<xref ref-type="bibr" rid="hanspub.28836-ref12">12</xref>] 。研究证实，CP和AVP水平呈正相关，其生物学效应稳定并可快速检测，因此作为AVP的理想替代。目前和肽素在HF中的研究较多，但对HFpEF的相对较少。研究表明HF患者血浆CP水平的升高是判断重度</p><p>HF预后的理想指标，预测死亡的价值优于BNP。CP是否可用于HFpEF的诊断需进一步研究证实。</p></sec></sec><sec id="s6_2"><title>4.2. 炎症相关生物标志物</title><sec id="s6_2_1"><title>4.2.1. 高敏C反应蛋白(hs-CRP)</title><p>C反应蛋白(CRP)主要是由肝脏合成和分泌的，是敏感的反应机体炎症的指标。当组织受损和炎症刺激时，CRP被肝细胞迅速释放到血液中。Hs-CRP和CRP是同一种蛋白，由于常规检测方法检测CRP浓度范围较窄，且目前临床已采用超敏检测技术来测定血清中较低浓度的hs-CRP。近年来研究发现，炎症在HF的发病机制中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.28836-ref13">13</xref>] ，因此hs-CRP成为心衰血清标志物之一。研究证明，hs-CRP联合BNP可以为诊断HF提供更多的信息 [<xref ref-type="bibr" rid="hanspub.28836-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.28836-ref15">15</xref>] 。</p></sec><sec id="s6_2_2"><title>4.2.2. 肿瘤坏死因子-α (TNF-α)</title><p>TNF-α由活化的巨噬细胞产生，可引起血管内皮细胞损伤，诱发心肌收缩力下降及心肌细胞凋亡 [<xref ref-type="bibr" rid="hanspub.28836-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.28836-ref17">17</xref>] 。作用机制为TNF-α刺激一氧化氮酶，增加一氧化氮合成，减弱心肌收缩力；导致心室重构，心肌细胞凋亡，严重影响患者预后。当患者HF时，TNF-α表达增强，使其介导的炎症反应启动。有研究显示：心衰程度越重，TNF-α水平升高越明显 [<xref ref-type="bibr" rid="hanspub.28836-ref18">18</xref>] 。TNF-α在临床上可作为检测HF进程的指标。</p></sec></sec><sec id="s6_3"><title>4.3. 与细胞外基质重构、纤维化有关的生物标志物</title><sec id="s6_3_1"><title>4.3.1. 半乳糖凝集素-3 (Gal-3)</title><p>Gal-3是由活化的巨噬细胞分泌的β-半乳糖苷结合蛋白，其能促进炎症反应和心脏纤维化 [<xref ref-type="bibr" rid="hanspub.28836-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.28836-ref20">20</xref>] 。既往大量研究表明，Gal-3能促进心脏巨噬细胞浸润，刺激成巨噬细胞和成纤维母细胞活化，使心肌成纤维细胞增殖及胶原沉积。国外研究证实，血浆Gal-3的表达水平，急、慢性HF患者明显高于非心力衰竭患者，是心肌纤维化和心室重构的生物标记物，同时也是HF预后的独立预测因素 [<xref ref-type="bibr" rid="hanspub.28836-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.28836-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.28836-ref23">23</xref>] 。Yin等 [<xref ref-type="bibr" rid="hanspub.28836-ref24">24</xref>] 对30例HFpEF的心力衰竭患者和45例正常人进行检测血清Gal-3水平，结果为HFpEF组患者的血清Gal-3水平明显高于对照组，差异有统计学意义。Gal-3水平对于HFpEF的预后价值大于HFrEF的心力衰竭患者。</p></sec><sec id="s6_3_2"><title>4.3.2. 可溶性基质裂解素-2 (sST-2)</title><p>ST-2蛋白又称为人基质裂解素，是白介素-1 (IL-1)受体家族成员之一，主要分为可溶性ST-2 (sST-2)和ST-2跨膜型(ST2L)两种类型，前者在血液中可被检测。Sst-2可竞争性抑制IL-33与ST2L的结合，导致炎症反应和心肌纤维化，进一步导致心肌舒张功能不全及心力衰竭的发展。</p></sec></sec><sec id="s6_4"><title>4.4. 肾功能标志物</title><sec id="s6_4_1"><title>4.4.1. 胱抑素C(CysC)</title><p>CysC，1968年首次发现，是一种半胱氨酸蛋白酶抑制剂，其最主要生理功能是抑制内源性半胱氨酸蛋白酶的活性，在一定程度上避免细胞免被蛋白酶水解。研究表明，病理条件下，由于半胱氨酸蛋白酶与其抑制剂之间失去平衡，导致胶原蛋白的分解减少，使大量胶原在血管周围及间质累积，进而导致心肌细胞外基质成分增多及纤维化形成，最终导致心室结构重构的发生。Matthias等 [<xref ref-type="bibr" rid="hanspub.28836-ref25">25</xref>] 发现，在CHF患者中，CysC不仅独立预测CHF的不良心血管事件，同时也是预后的独立危险因素。</p></sec></sec><sec id="s6_5"><title>4.5. 其他生物标志物</title><sec id="s6_5_1"><title>4.5.1. 微小RNA (miRNA)</title><p>miRNA是一类单链非编码RNA小分子，主要通过抑制mRNA翻译或促进其降解来调控基因的表达。目前已证实miR-1、miR-133、miR-208和miR-499等在心肌组织中表达，miRNA在血清中较稳定。大量试验已证实，miRNA与心衰的相关性，因此使其成为心衰生物学标志物成为可能。miRNA作为新型HF生物学标记物，已引起广泛关注，但缺乏大样本的对照研究，广泛应用于临床可能仍需一段时间。</p></sec><sec id="s6_5_2"><title>4.5.2. 生长分化因子-15 (GDF-15)</title><p>GDF-15属于转化生长因子(TGF-β)家族成员，正常生理情况下，GDF-15在前列腺和胎盘中高表达，在其他组织和器官中几乎不表达，但在机体心肌缺血/再灌注损伤、心力衰竭等病理状态下表达会明显增加 [<xref ref-type="bibr" rid="hanspub.28836-ref26">26</xref>] 。最新研究显示，GDF-15既可抗心肌细胞肥大，也可促进心肌成纤维细胞的生长和胶原沉积 [<xref ref-type="bibr" rid="hanspub.28836-ref27">27</xref>] 。近年来研究发现，GDF-15水平不仅可以作为诊断HFpEF的生物标志物，同时可以用于判断预后。2012年Baessler A等 [<xref ref-type="bibr" rid="hanspub.28836-ref28">28</xref>] 做了一项关于NT-proBNP和GDF-15在肥胖症合并HFpEF患者的研究发现：1) GDF-15水平在此类患者中明显升高，2) 此类患者GDF-15比NT-proBNP能更充分的表达心肌对慢性超负荷的反应。</p></sec></sec></sec><sec id="s7"><title>5. 总结</title><p>HFpEF的病理生理变化复杂，目前仍需深入研究其发展机制及特异的诊断方法。对生物标志物的深入研究，有助于为HFpEF更精确的诊断和判断预后方面开辟新思路。</p></sec><sec id="s8"><title>文章引用</title><p>邵淑梅,韩肖肖,谷秀娟. 左室射血分数保留的心力衰竭的研究进展Progress in the Study of Heart Failure with Left Ventricular Ejection Fraction Retention[J]. 临床医学进展, 2019, 09(02): 121-126. https://doi.org/10.12677/ACM.2019.92020</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28836-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehw128</mixed-citation></ref><ref id="hanspub.28836-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lam, C.S., Roger, V.L., Rodeheller, R.J., et al. (2007) Cardiac Structure and Ventricular-Vascular Function in Persons with Heart Failure and Preserved Ejection Fraction from Olmsted County. Minnesota. Circulation, 115, 1982-1990.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.106.659763</mixed-citation></ref><ref id="hanspub.28836-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">周鹍, 逯金金, 林谦. 舒张性心力衰竭研究进展[J]. 中西医结合心脑血管病杂志, 2015(13): 20-22.</mixed-citation></ref><ref id="hanspub.28836-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lubine, E., De Maria, A., Krishnoswamy, P., et al. (2002) Utility of Bnatrinretie Peptide in Detecting Diastolic Dysfunction. Circulation, 105, 595-601.</mixed-citation></ref><ref id="hanspub.28836-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">郭继鸿. 舒张性心衰的新理念[J]. 临床心电学杂志, 2009, 18(3): 209-221.</mixed-citation></ref><ref id="hanspub.28836-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Massie, B.M., Carson, P.E., MeMurry, J.J., et al. (2008) Irheganm in Patients with Heart Failure and Preserved Ejection Fraction. The New England Journal of Medicine, 359, 2456-2467.</mixed-citation></ref><ref id="hanspub.28836-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Coletta, A.P., Cullington, D., Clark, A.L. and Cleland, J.G.F. (2008) Clinical Trials Update from European Society of Cardiology Meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF and HOME-HF. Euro-pean Journal of Heart Failure, 10, 1264-1267. &lt;br&gt;https://doi.org/10.1016/j.ejheart.2008.10.002</mixed-citation></ref><ref id="hanspub.28836-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">von Haehling, S., Jankowska, E.A., Morgenthaler, N.G., et al. (2007) Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 50, 1973-1980. &lt;br&gt;https://doi.org/10.1016/j.jacc.2007.08.012</mixed-citation></ref><ref id="hanspub.28836-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张晓伟, 刘广忠, 李悦. 心衰生物标记物研究新进展[J]. 现代生物医学进展, 2015, 15(3): 558-561.</mixed-citation></ref><ref id="hanspub.28836-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Kardiologia Polska, 74, 1037-1147. &lt;br&gt;https://doi.org/10.5603/KP.2016.0141</mixed-citation></ref><ref id="hanspub.28836-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Holwerda, D. (1972) A Glyeopeptide from the Posterior Lobe of Pig Pituitaries I Isolation and Characterization. European Journal of Biochemistry, 28, 334-339. &lt;br&gt;https://doi.org/10.1111/j.1432-1033.1972.tb01918.x</mixed-citation></ref><ref id="hanspub.28836-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Dobša, L. and Cullen Edozien, K. (2013) Copeptin and Its Potential Role in Diagnosis and Prognosis of Various Diseases. Biochemia Medica, 23, 172-190. &lt;br&gt;https://doi.org/10.11613/BM.2013.021</mixed-citation></ref><ref id="hanspub.28836-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Torre-Amione, G. (2005) Immune Activation in Chronic Heart Failure. The American Journal of Cardiology, 95, 3-8. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2005.03.006</mixed-citation></ref><ref id="hanspub.28836-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Campbell, D.J., Woodward, M., Chalmers, J.P., et al. (2005) Prediction of Heart Failure by Amino Terminal-pro-B-type Natriuretic Peptide and C-Reactive Protein in Subjects with Cerebrovascular Disease. Hypertension, 45, 69-74.  
&lt;br&gt;https://doi.org/10.1161/01.HYP.0000151103.02424.c3</mixed-citation></ref><ref id="hanspub.28836-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ishikawa, C., Tsutamoto, T., Fujii, M., et al. (2006) Prediction of Mortality by High-Sensitivity C-Reactive Protein and Brain Natriuretic Peptide in Patients with Dilated Cardiomyopathy. Circulation Journal, 70, 857-863.</mixed-citation></ref><ref id="hanspub.28836-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nikolic, V.N., Jevtovic-Stoimenov, T., Stokanovic, D., et al. (2013) An Inverse Correlation between TNF-Alpha Serum Levels and Heart Rate Variability in Patients with Heart Failure. Journal of Cardiology, 62, 37-43.  
&lt;br&gt;https://doi.org/10.1016/j.jjcc.2013.02.013</mixed-citation></ref><ref id="hanspub.28836-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Tsarouhas, K., Tsitsimpikou, C., Haliassos, A., et al. (2011) Study of Insulin Resistance, TNF-Alpha, Total Antioxidant Capacity and Lipid Profile in Patients with Chronic Heart Failure under Exercise. In Vivo, 25, 1031-1037.</mixed-citation></ref><ref id="hanspub.28836-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">侯媛媛, 王志娟. 肿瘤坏死因子检测在心衰患者中的临床意义[J]. 福建医药杂志, 2004, 26(2): 112.</mixed-citation></ref><ref id="hanspub.28836-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Hrynchyshyn, N., Jourdain, P., Desnos, M., et al. (2013) Galectin-3: A New Bi-omarker for the Diagnosis, Analysis and Prognosis of Acute and Chronic Heart Failure. Archives of Cardiovascular Diseases, 106, 541-546.  
&lt;br&gt;https://doi.org/10.1016/j.acvd.2013.06.054</mixed-citation></ref><ref id="hanspub.28836-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Morrow, D.A. and O’Donoghue, M.L. (2012) Galectin-3 in Car-diovascular Disease: A Possible Window into Early Myocardial Firosis. Journal of the American College of Cardiology, 60, 1257-1258.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2012.05.032</mixed-citation></ref><ref id="hanspub.28836-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">de Boer, R.A., Lok, D.J., Jaarsma, T., et al. (2011) Predictive Value of Plasma Galectin-3 Levels in Heart Failure with Reduced and Preserved Ejection Fraction. Annals of Medicine, 43, 60-68.  
&lt;br&gt;https://doi.org/10.3109/07853890.2010.538080</mixed-citation></ref><ref id="hanspub.28836-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Motiwala, S.R., Szymonifka, J., Belcher, A., et al. (2013) Serial Measurement of Galectin-3 in Patients with Chronic Heart Failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. European Journal of Heart Failure, 15, 1157-1163. &lt;br&gt;https://doi.org/10.1093/eurjhf/hft075</mixed-citation></ref><ref id="hanspub.28836-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wu, A.H., Wians, F. and Jaffe, A. (2013) Biological Variation of Ga-lectine-3 and Soluble ST2 for Chronic Heart Failure: Implication on Interpretation of Test Results. American Heart Journal, 165, 995-999.  
&lt;br&gt;https://doi.org/10.1016/j.ahj.2013.02.029</mixed-citation></ref><ref id="hanspub.28836-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yin, Q.S., Shi, B., Dong, L., et al. (2014) Comparative Study of Galectin-3 and B-Type Natriuretic Peptide as Biomarkers for the Diagnosis of Heart Failure. Journal of Geriatric Car-diology, 11, 79-82.</mixed-citation></ref><ref id="hanspub.28836-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Dupont, M., Wu, Y., Hazen, S.L., et al. (2012) Cystatin C Identifies Patients with Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. Circulation Heart Failure, 5, 602-609.  
&lt;br&gt;https://doi.org/10.1161/CIRCHEARTFAILURE.112.966960</mixed-citation></ref><ref id="hanspub.28836-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Yan, Y. (2010) The Mechanism of Coronary Artery Ectasia and Endothelial Protection of Growth Differentiation Factor-15. Chinese Peking Union Medical College, Beijing.</mixed-citation></ref><ref id="hanspub.28836-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Li, Z. and Gao, W. (2011) Growth Differentiation Factor 15 in Cardiovascular Diseases: From Bench to Bedside. Biomarkers, 16, 466-475. &lt;br&gt;https://doi.org/10.3109/1354750X.2011.580006</mixed-citation></ref><ref id="hanspub.28836-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Baessler, A., Strack, C., Rousseva, E., et al. (2012) Growth-Differentiation Factor-15 Improves Reclassification for the Diagnosis of Heart Failure with Normal Ejection Fraction in Morbid Obesity. European Journal of Heart Failure, 14, 1240-1248. &lt;br&gt;https://doi.org/10.1093/eurjhf/hfs116</mixed-citation></ref></ref-list></back></article>